The effect of size and aspect ratio of Fe-MIL-88B-NH2 metal-organic frameworks on their relaxivity and contrast enhancement properties in MRI: in vitro and in vivo studies

2018 ◽  
Vol 20 (10) ◽  
Author(s):  
Sadegh Dehghani ◽  
Nader Riahi Alam ◽  
Shahriar Shahriarian ◽  
Tohid Mortezazadeh ◽  
Soheila Haghgoo ◽  
...  
Author(s):  
Ines Sifaoui ◽  
Idaira Pacheco-Fernández ◽  
José E. Piñero ◽  
Verónica Pino ◽  
Jacob Lorenzo-Morales

In this study, the application of amphipods in vivo assays was evaluated. The main aim of this work was to check the potential use of this model in biocompatibility assessments of metal-organic frameworks (MOFs). Hence, six different MOFs were synthesized and the in vitro and ex vivo cytotoxicity was first assessed using a colorimetric assay and a macrophage cell line. Obtained results were compared to validate the in vivo toxicity tests carried out using amphipods and increasing concentrations of the different MOFs. Amphipods do not require the need of ethics approval and also are less expensive to keep than conventional in vivo models, showing its potential as a fast and reliable platform in toxicity studies. The obtained results showed that the amphipods based-assay was simple, easy to replicate and yielded toxicity data corresponding to the type of MOFs tested. In addition, it was observed that only CIM-80(Al) and CIM-84(Zr) did not show any toxicity to the animals at the different tested concentrations. Therefore, the developed in vivo model could be applied as a high-throughput toxicity screening method to evaluate the toxicity of numerous materials, chemicals and therapeutic agents among others.


2020 ◽  
Vol 10 (8) ◽  
pp. 1197-1203
Author(s):  
Dawei Liu ◽  
Bing Bai ◽  
Yanbin Sun ◽  
Youxin Guo

It is well known that nanoscale metal-organic frameworks (NMOFs) have exhibited brilliant advantages in cancer diagnosis and treatment due to their structural diversity, high intrinsic biodegradability, and drug-loading capacities. Herein, based on our previous results, hypoxia was suppressed by inhibiting the expression of the CA IX protein, produced from Zr-MOF nanoparticles, and enhancing radiation therapy (RT) effectiveness. We designed a nanocomposite by encapsulating doxorubicin into Zr-MOF nanoparticles. It is a highly effective drug for chemotherapy and MOF that can absorb X-rays well, applied to enhance RT as the radiosensitizer. PEG is used for surface modification in the nanoparticles and to improve circulation time by intravenous administration. These nanoparticles could be applied for RT combing with chemotherapy in vitro and vivo, obtaining excellent anticancer efficacy. Most importantly, Zr-MOF@Dox demonstrates high clearance from HepG2 tumor cells, reducing the circulation of toxicity in vivo. Our research exhibits a new approach to establishing Zr-MOF@Dox as a biodegradable drug-carrier system, containing chemotherapy drugs and functional elements that totally perform the diagnosis and treatment roles of RT.


2017 ◽  
Vol 5 (12) ◽  
pp. 2330-2336 ◽  
Author(s):  
Tao Zhang ◽  
Lei Wang ◽  
Chong Ma ◽  
Weiqi Wang ◽  
Jun Ding ◽  
...  

A new computed tomography (CT) imaging agent is developed based on the BODIPY-containing nanoscale metal–organic frameworks (NMOFs). The bio-safety and CT imaging of such NMOFs have been well investigated both in vitro and in vivo.


2020 ◽  
Vol 111 ◽  
pp. 110774 ◽  
Author(s):  
Iliya Kritskiy ◽  
Tatyana Volkova ◽  
Tatyana Sapozhnikova ◽  
Anton Mazur ◽  
Peter Tolstoy ◽  
...  

2018 ◽  
Vol 14 (1) ◽  
pp. 16
Author(s):  
Qonita Awliya Hanif ◽  
Reva Edra Nugraha ◽  
Witri Wahyu Lestari

<p><em>Metal–Organic Frameworks</em> (MOFs) merupakan material berpori baru yang berpotensi sebagai pengantar dan pelepas lambat obat. Strukturnya yang fleksibel, ukuran pori kristalin yang teratur, dan sisi koordinasi yang beragam merupakan beberapa kelebihan dari MOFs yang mendukung dalam enkapsulasi berbagai obat. Metode yang dapat digunakan untuk sintesis MOFs diantaranya nanopresipitasi, <em>solvothermal</em>, <em>reverse microemulsion</em>, dan reaksi <em>solvothermal</em> dengan template surfaktan. Karakterisasi material hasil sintesis maupun profil setelah enkapsulasi (<em>loading</em>) dapat dilakukan menggunakan <em>Scanning Electron Micrscope</em> (SEM), <em>Transmission Electron Microscope</em> (TEM), <em>Differential Scanning Calorymetry</em> (DSC), <em>Fourier Transform Infra Red Spectroscopy</em> (FTIR), dan <em>Powder X-Ray Diffraction </em>(PXRD). Metode <em>loading</em> obat terdiri dari dua kategori, yakni penggabungan agen biomedis secara langsung dan <em>loading</em> secara <em>post synthesis</em>. Sebelum MOFs diaplikasikan, perlu dilakukan aktivasi dan penempelan material obat. Pengujian lepas lambat dapat dijalankan pada beberapa kondisi seperti dalam <em>Simulated Body Fluid</em> (SBF), <em>Phosphate Buffer Saline</em> (PBS), <em>Bovine Serum Albumin</em> (BSA) maupun simulasi menggunakan <em>Grand Canonical Monte Carlo</em> (GCMC). Pengujian secara <em>in vivo</em> dan <em>in vitro</em> juga dapat dilakukan untuk mengetahui dampaknya pada tubuh makhluk hidup dan aktivitasnya terhadap sel patogen. Kombinasi organik <em>linker</em> dan ion logam pusat yang berbeda akan menghasilkan ukuran pori, fleksibilitas, kapasitas <em>loading</em>, profil pelepasan obat, toksisitas, dan kemampuan menginhibisi yang berbeda pula. Pada review kali ini akan dibahas tentang kajian singkat terkait struktur dan desain MOFs, bio-MOFs, nano bio MOFs, strategi sintesis, dan strategi <em>loading</em> dan pelepasan obat untuk aplikasi dalam biomedis. Selanjutnya akan diberikan beberapa contoh aplikasi yang sudah dilakukan sejauh ini misalnya beberapa jenis MOFs yang sudah dienkapsulasi dengan beberapa material obat, seperti 5-fluoracil, ibuprofen, doxorubicin, dan dikaji waktu pelepasannya dan interaksinya dengan permodelan komputasi.</p><p><strong>Study of Metal–Organic Frameworks (M</strong><strong>OF</strong><strong>s) as </strong><strong>a</strong><strong> Novel Material for Drug Delivery</strong>. Metal–Organic Frameworks (MOFs) are a novel class of porous material that has wide potential applications including in drug delivery and slow release. Its flexible structure, regular crystalline pore size, and various coordination sites are some of the advantages of supporting MOFs properties in the encapsulation of various drugs. Various methods can be used for the MOFs synthesis include nanoprecipitation, solvothermal, reverse micro emulsion, and surfactant-templated solvothermal. Both characterization for synthesized materials and profile after encapsulation can be done using Scanning Electron Microscope (SEM), Transmission Electron Microscope (TEM), Differential Scanning Calorimetry (DSC), Fourier Transform Infra-Red Spectroscopy (FTIR), and Powder X-Ray Diffraction (PXRD). The drug loading method consists of two categories, namely the direct incorporation of biomedical agents and post-synthesis method. Before MOFs are applied in biomedical application, activation and attachment of medicinal materials should be performed. Meanwhile, for slow release testing can be run on several conditions such as in Simulated Body Fluid (SBF), Phosphate Buffer Saline (PBS), Bovine Serum Albumin (BSA) and simulation using Grand Canonical Monte Carlo (GCMC). In vivo and in vitro testing can also be done to determine the impact on the body of living creatures and their activity on pathogen cells. Different organic linker and metal center combinations will result in pore size, flexibility, loading capacity, drug release profiles, toxicity, and different inhibiting ability. Herein, we will discuss a brief review of the structure and design of MOFs, bio-MOFs, nano-bio MOFs, synthesis, drug loading and release strategies for applications in biomedicine. Furthermore, there will be some examples of applications that have been done so far, e.g. some types of MOFs that have been encapsulated with some medicinal materials, such as 5-fluorouracil, ibuprofen, doxorubicin, and reviewed its release time and interaction with computational modeling.</p>


2021 ◽  
pp. 129386
Author(s):  
A. Ringaci ◽  
A.V. Yaremenko ◽  
K.G. Shevchenko ◽  
S.D. Zvereva ◽  
M.P. Nikitin

2001 ◽  
Vol 5 (8) ◽  
pp. 645-651
Author(s):  
M. Peeva ◽  
M. Shopova ◽  
U. Michelsen ◽  
D. Wöhrle ◽  
G. Petrov ◽  
...  
Keyword(s):  

2005 ◽  
Vol 25 (1_suppl) ◽  
pp. S198-S198
Author(s):  
Joseph R Meno ◽  
Thien-son K Nguyen ◽  
Elise M Jensen ◽  
G Alexander West ◽  
Leonid Groysman ◽  
...  

1994 ◽  
Vol 72 (06) ◽  
pp. 942-946 ◽  
Author(s):  
Raffaele Landolfi ◽  
Erica De Candia ◽  
Bianca Rocca ◽  
Giovanni Ciabattoni ◽  
Armando Antinori ◽  
...  

SummarySeveral “in vitro” and “in vivo” studies indicate that heparin administration may affect platelet function. In this study we investigated the effects of prophylactic heparin on thromboxane (Tx)A2 biosynthesis “in vivo”, as assessed by the urinary excretion of major enzymatic metabolites 11-dehydro-TxB2 and 2,3-dinor-TxB2. Twenty-four patients who were candidates for cholecystectomy because of uncomplicated lithiasis were randomly assigned to receive placebo, unfractionated heparin, low molecular weight heparin or unfractionaed heparin plus 100 mg aspirin. Measurements of daily excretion of Tx metabolites were performed before and during the treatment. In the groups assigned to placebo and to low molecular weight heparin there was no statistically significant modification of Tx metabolite excretion while patients receiving unfractionated heparin had a significant increase of both metabolites (11-dehydro-TxB2: 3844 ± 1388 vs 2092 ±777, p <0.05; 2,3-dinor-TxB2: 2737 ± 808 vs 1535 ± 771 pg/mg creatinine, p <0.05). In patients randomized to receive low-dose aspirin plus unfractionated heparin the excretion of the two metabolites was largely suppressed thus suggesting that platelets are the primary source of enhanced thromboxane biosynthesis associated with heparin administration. These data indicate that unfractionated heparin causes platelet activation “in vivo” and suggest that the use of low molecular weight heparin may avoid this complication.


Sign in / Sign up

Export Citation Format

Share Document